Transdermal drug delivery system containing donepezil
The present invention provides a transdermal drug delivery system comprising a drug-containing matrix layer comprising: (a) donepezil or a pharmaceutically acceptable salt thereof as an active ingredient; and (b) an acrylate-rubber hybrid as an adhesive.
1. A transdermal drug delivery system consisting of a backing layer, a drug-containing matrix layer and a release layer, the drug-containing matrix layer comprising: (a) donepezil or a pharmaceutically acceptable salt thereof as an active ingredient; and (b) an acrylate-rubber hybrid as an adhesive to increase skin penetration rate,
wherein donepezil or its pharmaceutically acceptable salt is an amount of 5 to 40% by weight and the acrylate-rubber hybrid is an amount of 60 to 90% by weight, each based on the total weight of the drug-containing matrix layer, and
an acrylic polymer of the acrylate-rubber hybrid comprises a C 4 ˜C 18 alkyl acrylate monomer grafted with a rubber macromer having a glass transition temperature of not more than −30° C.
2. The transdermal drug delivery system of claim 1 , wherein the drug-containing matrix layer further comprises an acrylate polymer or a methacrylate polymer as a crystallization-inhibiting agent.
3. The transdermal drug delivery system of claim 2 , wherein the crystallization-inhibiting agent is present in an amount ranging from 1 to 10% by weight, based on the total weight of the drug-containing matrix layer.
4. The transdermal drug delivery system of claim 2 , wherein the crystallization-inhibiting agent is a copolymer of butyl methacrylate, 2-dimethylaminoethyl methacrylate, and methyl methacrylate in a weight ratio of 1:2:1.
5. The transdermal drug delivery system of claim 1 , wherein the drug-containing matrix layer further comprises one or more absorption enhancers selected from the group consisting of terpenes, surfactants, polyoxyethylene alkyl ethers, fatty alcohols, sugar esters, glycerols, alkyl 2-ethyl hexanates, and diethoxylethyl succinates.
6. The transdermal drug delivery system of claim 5 , wherein the absorption enhancer is present in an amount ranging from 1 to 20% by weight, based on the total weight of the drug-containing matrix layer.
7. The transdermal drug delivery system of claim 5 , wherein the absorption enhancer is one or more selected from the group consisting of polyethylene glycol palm kernel glyceride, polyoxyethylene lauryl ether, polyglyceryl-3 oleate, lauryl alcohol, and oleyl alcohol.